Under the agreement, Neomorph will receive an undisclosed upfront payment from AbbVie and be eligible for up to $1.64 billion in aggregate option fees and milestones.

Just because Wall Street likes a stock doesn't mean it's a great pick. However, it's not a bad idea to at least consider how ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Novo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...

Novo Nordisk has faced a massive selloff in recent months amid disappointing drug trials and U.S. pressure to cut its prices.

Medicare announced plans to negotiate lower prices for 15 costly drugs, including Ozempic, Wegovy, and Trelegy Ellipta, ...

Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo ...